Korean study monitors prevenar 20 vaccine safety
NCT ID NCT06760208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking how safe the Prevenar 20 vaccine is once it's used in Korea. About 660 people aged 6 weeks and older who are prescribed the vaccine will get one dose. Researchers will track any side effects for 28 days after vaccination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 660 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population for this study is subjects aged 6 weeks or older who are determined to be administered Pneumococcal 20-valent conjugate vaccine according to the approved indications in routine clinical practice in Republic of Korea.
- Ages
-
6 weeks and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Infant, children and adolescents who are aged 6 weeks to under 18 years or adult who are 18 years or older 2. Subjects who have been prescribed Prevenar 20 by their physician as per approved product label 3. Evidence of a personally signed and dated informed consent document indicating that the subject or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study Exclusion Criteria: Subjects meeting any of the following criteria will not be included in the study: 1. Subjects with contraindication according to approved label of Prevernar 20 (Pneumococcal 20-valent conjugate vaccine) 2. Any subjects (or a legally acceptable representative) who do not agree that Pfizer and companies working with Pfizer use his/her information
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pneumococcal immunization are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Pfizer Korea
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Caregiver's opinion sway an older Adult's decision to get the pneumonia vaccine?
- Can a new cosmetic pass the skin allergy test?
- Can a new drug pair tame hodgkin lymphoma in older patients?
- Can a new injection shrink advanced solid tumors?
- Can a two-drug combo better tame prostate trouble?
- New vaginal capsule aims to tackle stubborn bacterial vaginosis